Autoimmune T cell engagers diverge from their oncology roots

A burst of deals last month gave T cell engagers new credibility as a potential modality for B cell depletion in autoimmune diseases, with the promise of greater efficacy than mAbs and less manufacturing complexity than CAR Ts. But clinical evidence for that proposition is still sparse.

As biopharmas reposition T cell-engaging multispecifics from cancer to autoimmunity, the question is whether modified dosing strategies and other safety measures will be enough, or whether fit-for-purpose therapies will be needed...